BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35805163)

  • 1. Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway.
    Sun Q; Lu Z; Zhang Y; Xue D; Xia H; She J; Li F
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
    Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
    Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.
    Osude C; Lin L; Patel M; Eckburg A; Berei J; Kuckovic A; Dube N; Rastogi A; Gautam S; Smith TJ; Sreenivassappa SB; Puri N
    Cells; 2022 May; 11(10):. PubMed ID: 35626731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
    Yang YM; Jang Y; Lee SH; Kang B; Lim SM
    Lung Cancer; 2020 Aug; 146():70-77. PubMed ID: 32521387
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β-catenin pathway in NSCLC.
    Wang J; Zhou P; Wang X; Yu Y; Zhu G; Zheng L; Xu Z; Li F; You Q; Yang Q; Zhuo W; Sun J; Chen Z
    Cell Prolif; 2019 May; 52(3):e12592. PubMed ID: 30848009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
    Wu F; Li J; Jang C; Wang J; Xiong J
    Int J Clin Exp Pathol; 2014; 7(10):6653-61. PubMed ID: 25400744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer.
    Xu C; Jiang ZB; Shao L; Zhao ZM; Fan XX; Sui X; Yu LL; Wang XR; Zhang RN; Wang WJ; Xie YJ; Zhang YZ; Nie XW; Xie C; Huang JM; Wang J; Wang J; Leung EL; Wu QB
    Pharmacol Res; 2023 May; 191():106739. PubMed ID: 36948327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGFβ1/integrin β3 positive feedback loop contributes to acquired EGFR TKI resistance in EGFR-mutant lung cancer.
    Wang T; Zhang Y; Cheng H; Li L; Xu L
    J Drug Target; 2023 Mar; 31(3):269-277. PubMed ID: 36217893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression.
    Safaric Tepes P; Pal D; Lindsted T; Ibarra I; Lujambio A; Jimenez Sabinina V; Senturk S; Miller M; Korimerla N; Huang J; Glassman L; Lee P; Zeltsman D; Hyman K; Esposito M; Hannon GJ; Sordella R
    Elife; 2021 Jul; 10():. PubMed ID: 34254585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.
    Ghiso E; Migliore C; Ciciriello V; Morando E; Petrelli A; Corso S; De Luca E; Gatti G; Volante M; Giordano S
    Neoplasia; 2017 Dec; 19(12):1012-1021. PubMed ID: 29136529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
    Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
    Wang L; Dong X; Ren Y; Luo J; Liu P; Su D; Yang X
    Cell Death Dis; 2018 Jan; 9(2):129. PubMed ID: 29374157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
    Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
    Byers LA; Diao L; Wang J; Saintigny P; Girard L; Peyton M; Shen L; Fan Y; Giri U; Tumula PK; Nilsson MB; Gudikote J; Tran H; Cardnell RJ; Bearss DJ; Warner SL; Foulks JM; Kanner SB; Gandhi V; Krett N; Rosen ST; Kim ES; Herbst RS; Blumenschein GR; Lee JJ; Lippman SM; Ang KK; Mills GB; Hong WK; Weinstein JN; Wistuba II; Coombes KR; Minna JD; Heymach JV
    Clin Cancer Res; 2013 Jan; 19(1):279-90. PubMed ID: 23091115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone deacetylase SIRT6 promotes glycolysis through the HIF-1α/HK2 signaling axis and induces erlotinib resistance in non-small cell lung cancer.
    You Q; Wang J; Yu Y; Li F; Meng L; Chen M; Yang Q; Xu Z; Sun J; Zhuo W; Chen Z
    Apoptosis; 2022 Dec; 27(11-12):883-898. PubMed ID: 35915188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.